Agents that reduce oxidative stress allow survival of DUX4 expressing cells [204,237,238] and antioxidant complementation was tested in a clinical trial for FSHD [202]: these antioxidants might also affect HIF-1α which is stabilized by ROS. The gene discussed is HIF1A; the disease is facioscapulohumeral muscular dystrophy.